Clonidine extended-release tablets for the treatment of ADHD

Joan Daughton, Lindsey Corr, Howard Y Liu, Madeline Jennifer West

Research output: Contribution to journalReview article

Abstract

Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15% of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay™, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
JournalNeuropsychiatry
Volume2
Issue number2
DOIs
StatePublished - Apr 1 2012

Fingerprint

Clonidine
Tablets
Therapeutics
Guidelines

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Clonidine extended-release tablets for the treatment of ADHD. / Daughton, Joan; Corr, Lindsey; Liu, Howard Y; West, Madeline Jennifer.

In: Neuropsychiatry, Vol. 2, No. 2, 01.04.2012, p. 117-123.

Research output: Contribution to journalReview article

@article{76531b95ea54453389e8a1bc8d1999f7,
title = "Clonidine extended-release tablets for the treatment of ADHD",
abstract = "Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15{\%} of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay™, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.",
author = "Joan Daughton and Lindsey Corr and Liu, {Howard Y} and West, {Madeline Jennifer}",
year = "2012",
month = "4",
day = "1",
doi = "10.2217/npy.12.7",
language = "English (US)",
volume = "2",
pages = "117--123",
journal = "Neuropsychiatry",
issn = "1758-2008",
publisher = "University of Virginia",
number = "2",

}

TY - JOUR

T1 - Clonidine extended-release tablets for the treatment of ADHD

AU - Daughton, Joan

AU - Corr, Lindsey

AU - Liu, Howard Y

AU - West, Madeline Jennifer

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15% of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay™, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.

AB - Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15% of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay™, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.

UR - http://www.scopus.com/inward/record.url?scp=84876509084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876509084&partnerID=8YFLogxK

U2 - 10.2217/npy.12.7

DO - 10.2217/npy.12.7

M3 - Review article

AN - SCOPUS:84876509084

VL - 2

SP - 117

EP - 123

JO - Neuropsychiatry

JF - Neuropsychiatry

SN - 1758-2008

IS - 2

ER -